Novavax (NVAX) Cash from Operations Growth (1y) (2011 - 2026)
Novavax (NVAX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 158.60% |
| 10 | Novavax | 1.26 Bn | 466.89 Mn | 108.82 Mn | 82.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.53% |
| Dec 31, 2025 | 77.20% |
| Sep 30, 2025 | 174.47% |
| Jun 30, 2025 | -140.57% |
| Mar 31, 2025 | -122.01% |
| Dec 31, 2024 | 2.05% |
| Sep 30, 2024 | -265.18% |
| Jun 30, 2024 | 282.78% |
| Mar 31, 2024 | 74.34% |
| Dec 31, 2023 | -50.05% |
| Sep 30, 2023 | -2.45% |
| Jun 30, 2023 | -0.61% |
| Mar 31, 2023 | -267.86% |
| Dec 31, 2022 | 65.59% |
| Sep 30, 2022 | 72.77% |
| Jun 30, 2022 | -218.34% |
| Mar 31, 2022 | -113.35% |
| Dec 31, 2021 | -166.32% |
| Sep 30, 2021 | -2,087.83% |
| Jun 30, 2021 | 24.89% |